139 related articles for article (PubMed ID: 16033998)
1. Targeting breast and prostate cancers through their hormone receptors.
Leuschner C; Hansel W
Biol Reprod; 2005 Nov; 73(5):860-5. PubMed ID: 16033998
[TBL] [Abstract][Full Text] [Related]
2. Destruction of breast cancers and their metastases by lytic peptide conjugates in vitro and in vivo.
Hansel W; Enright F; Leuschner C
Mol Cell Endocrinol; 2007 Jan; 260-262():183-9. PubMed ID: 17101210
[TBL] [Abstract][Full Text] [Related]
3. Conjugates of lytic peptides and LHRH or betaCG target and cause necrosis of prostate cancers and metastases.
Hansel W; Leuschner C; Enright F
Mol Cell Endocrinol; 2007 Apr; 269(1-2):26-33. PubMed ID: 17382461
[TBL] [Abstract][Full Text] [Related]
4. Targeted destruction of normal and cancer cells through lutropin/choriogonadotropin receptors using Hecate-betaCG conjugate.
Zaleska M; Bodek G; Jana B; Hansel W; Ziecik AJ
Exp Clin Endocrinol Diabetes; 2003 May; 111(3):146-53. PubMed ID: 12784188
[TBL] [Abstract][Full Text] [Related]
5. Effects of a lytic peptide conjugated to beta HCG on ovarian cancer: studies in vitro and in vivo.
Gawronska B; Leuschner C; Enright FM; Hansel W
Gynecol Oncol; 2002 Apr; 85(1):45-52. PubMed ID: 11925119
[TBL] [Abstract][Full Text] [Related]
6. Targeted destruction of prostate cancer cells and xenografts by lytic peptide-betaLH conjugates.
Hansel W; Leuschner C; Gawrońska B; Enright F
Reprod Biol; 2001 Jul; 1(1):20-32. PubMed ID: 14666172
[TBL] [Abstract][Full Text] [Related]
7. Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptors.
Leuschner C; Enright FM; Gawronska-Kozak B; Hansel W
Prostate; 2003 Sep; 56(4):239-49. PubMed ID: 12858351
[TBL] [Abstract][Full Text] [Related]
8. Membrane disrupting lytic peptide conjugates destroy hormone dependent and independent breast cancer cells in vitro and in vivo.
Leuschner C; Enright FM; Gawronska B; Hansel W
Breast Cancer Res Treat; 2003 Mar; 78(1):17-27. PubMed ID: 12611453
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapy for adrenocortical tumors in transgenic mice through their LH receptor by Hecate-human chorionic gonadotropin beta conjugate.
Vuorenoja S; Rivero-Müller A; Ziecik AJ; Huhtaniemi I; Toppari J; Rahman NA
Endocr Relat Cancer; 2008 Jun; 15(2):635-48. PubMed ID: 18509010
[TBL] [Abstract][Full Text] [Related]
10. Use of hecate-chorionic gonadotropin beta conjugate in therapy of lutenizing hormone receptor expressing gonadal somatic cell tumors.
Rivero-Müller A; Vuorenoja S; Tuominen M; Wacławik A; Brokken LJ; Ziecik AJ; Huhtaniemi I; Rahman NA
Mol Cell Endocrinol; 2007 Apr; 269(1-2):17-25. PubMed ID: 17363137
[TBL] [Abstract][Full Text] [Related]
11. A novel approach of targeted ablation of mammary carcinoma cells through luteinizing hormone receptors using Hecate-CGbeta conjugate.
Bodek G; Rahman NA; Zaleska M; Soliymani R; Lankinen H; Hansel W; Huhtaniemi I; Ziecik AJ
Breast Cancer Res Treat; 2003 May; 79(1):1-10. PubMed ID: 12779076
[TBL] [Abstract][Full Text] [Related]
12. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.
Nagy A; Schally AV
Biol Reprod; 2005 Nov; 73(5):851-9. PubMed ID: 16033997
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of Phor21-betaCG(ala), a lytic peptide conjugate.
Jia L; Noker PE; Piazza GA; Leuschner C; Hansel W; Gorman GS; Coward LU; Tomaszewski J
J Pharm Pharmacol; 2008 Nov; 60(11):1441-8. PubMed ID: 18957164
[TBL] [Abstract][Full Text] [Related]
14. A novel targeted therapy of Leydig and granulosa cell tumors through the luteinizing hormone receptor using a hecate-chorionic gonadotropin beta conjugate in transgenic mice.
Bodek G; Vierre S; Rivero-Müller A; Huhtaniemi I; Ziecik AJ; Rahman NA
Neoplasia; 2005 May; 7(5):497-508. PubMed ID: 15967102
[TBL] [Abstract][Full Text] [Related]
15. Targeted destruction of androgen-sensitive and -insensitive prostate cancer cells and xenografts through luteinizing hormone receptors.
Leuschner C; Enright FM; Melrose PA; Hansel W
Prostate; 2001 Feb; 46(2):116-25. PubMed ID: 11170139
[TBL] [Abstract][Full Text] [Related]
16. Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
Chatzistamou L; Schally AV; Nagy A; Armatis P; Szepeshazi K; Halmos G
Clin Cancer Res; 2000 Oct; 6(10):4158-65. PubMed ID: 11051271
[TBL] [Abstract][Full Text] [Related]
17. Hecate-CGbeta conjugate and gonadotropin suppression shows two distinct mechanisms of action in the treatment of adrenocortical tumors in transgenic mice expressing Simian Virus 40 T antigen under inhibin-alpha promoter.
Vuorenoja S; Mohanty BP; Arola J; Huhtaniemi I; Toppari J; Rahman NA
Endocr Relat Cancer; 2009 Jun; 16(2):549-64. PubMed ID: 19261682
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of tumor growth and elimination of multiple metastases in human prostate and breast xenografts by systemic inoculation of a host defense-like lytic peptide.
Papo N; Seger D; Makovitzki A; Kalchenko V; Eshhar Z; Degani H; Shai Y
Cancer Res; 2006 May; 66(10):5371-8. PubMed ID: 16707464
[TBL] [Abstract][Full Text] [Related]
19. Expression and regulation of luteinizing hormone/human chorionic gonadotropin receptors in ovarian cancer and its correlation to human chorionic gonadotropin-doxorubicin sensitivity.
Gebauer G; Mueller N; Fehm T; Berkholz A; Beck EP; Jaeger W; Licht P
Am J Obstet Gynecol; 2004 Jun; 190(6):1621-8; discussion 1628. PubMed ID: 15284756
[TBL] [Abstract][Full Text] [Related]
20. Targeted ablation of prostate carcinoma cells through LH receptor using Hecate-CGbeta conjugate: functional characteristic and molecular mechanism of cell death pathway.
Bodek G; Kowalczyk A; Waclawik A; Huhtaniemi I; Ziecik AJ
Exp Biol Med (Maywood); 2005 Jun; 230(6):421-8. PubMed ID: 15956772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
